Loading…
LIPOFUNDIN MCT/LCT is a brand name for Medium Chain Triglycerides. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Lipofundin MCT/LCT is indicated as a source of calories and essential fatty acids for patients requiring parenteral nutrition.
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Maximum daily doses should only be administered after stepwise increase with careful monitoring of the tolerance of the infusions. g. the severity of underlying disease, body weight, gestational and postnatal age and specific body functions.
) per day. g. oncology patients), should not be exceeded. /d. /d corresponds to a maximum daily dose of 700 ml Lipofundin MCT/LCT 20%. /d may be beneficial regarding the possibility to monitor the increase of the plasma triglyceride level and prevent hyperlipidaemia.
0 (max. /d of lipids. In preterm newborn infants, term newborn infants, infants and toddlers, the daily dose of lipids should be infused continuously over about 24 hours. /d. Infusion rate The infusion should be administered at the lowest possible infusion rate.
During the first 15 minutes the infusion rate should only be 50% of the maximum infusion rate to be used. The patient should be monitored closely for the occurrence of adverse reactions. /h lipids. 5 ml per hour Lipofundin MCT/LCT 20%.
5 g per hour. /h lipids. /h lipids. Method of administration Intravenous use. Lipid emulsions are suitable for peripheral venous administration and can also be administered separately via peripheral veins as part of total parenteral nutrition.
The Y- or the bypass connector should be placed as close to the patient as possible, if lipid emulsions are co-administered with amino acid and carbohydrate solutions. The duration of administration of Lipofundin MCT/LCT 20% is usually 1 - 2 weeks.
If parenteral nutrition with lipid emulsions is further indicated, Lipofundin MCT/LCT 20% can be administered over longer periods provided appropriate monitoring is employed. 6).
The following listing includes a number of systemic adverse reactions that may be associated with the use of Lipofundin MCT/LCT 20%. Under the conditions of correct use, in terms of dosing, monitoring, observation of safety restrictions and instructions, most of them are very rare (< 1/10,000).
g. anaphylactic reactions, dermal eruptions, laryngeal, oral and facial oedema) Metabolism and nutrition disorders Very rare: Hyperlipidaemia, hyperglycaemia, metabolic acidosis, ketoacidosis The frequency of these adverse reactions is dose-dependent and may be higher under conditions of absolute or relative overdose.
Nervous system disorders Very rare:
Headache, drowsiness Vascular disorders Very rare: Hypertension or hypotension, flush Respiratory, thoracic and mediastinal disorders Very rare: Dyspnoea, cyanosis Gastrointestinal disorders Very rare: Nausea, vomiting, loss of appetite Hepatobiliary disorders Not known: Cholestasis Skin and subcutaneous tissue disorders Very rare: Erythema, sweating Musculoskeletal and connective tissue disorders Very rare: Pain in the back, bones, chest and lumbar region General disorders and administration site conditions Very rare: Elevated body temperature, feeling cold, chills, fat overload syndrome (see below).
If adverse reactions occur, the infusion of Lipofundin MCT/LCT 20% must be stopped or, if necessary, continued at a reduced dosage. If the infusion is restarted, the patient must be carefully monitored, especially at the beginning, and serum triglycerides should be determined at short intervals.
Information on particular undesirable effects Nausea, vomiting, lack of appetite and hyperglycaemia are symptoms related to conditions constituting an indication for parenteral nutrition and may sometimes be associated with parenteral nutrition.
The serum triglyceride concentration should be regularly monitored during the infusion of Lipofundin MCT/LCT 20%. Depending on the patient’s metabolic condition, occasional hypertriglyceridaemia may occur. 6 mmol/l during administration of the lipid emulsion, it is recommended to reduce the infusion rate.
4 mmol/l. Disorders of the fluid, electrolyte or acid-base balance must be corrected before the start of infusion. Controls of serum electrolytes, fluid balance, acid-base balance, cardiovascular function and – during long-term administration – of blood cell counts, coagulation status, and hepatic function are necessary.
g. due to traces of protein in soya-bean oil or egg phospholipids for injection) are extremely rare, but cannot be totally excluded for sensitised patients. g. fever, shivering, rash, dyspnoea. Energy supply with lipid emulsions alone could cause metabolic acidosis.
It is therefore recommended to infuse an adequate quantity of intravenous carbohydrates and amino acids along with the fat emulsion. For patients requiring complete parenteral nutrition, complementary carbohydrate, amino acid, electrolyte, vitamin, and trace element supplements are required.
Also, an adequate total fluid intake has to be ensured. 6), both resulting in a high risk of embolism. g. Lipofundin MCT/LCT 20%), the ratio of emulsifier (phospholipid) to oil is lower than in lower concentrated lipid emulsions. This ensures a favourable lower plasma concentration of triglycerides, phospholipids, free fatty acids as well as the pathological lipoprotein-X in the patient`s blood.
Therefore higher concentrated lipid emulsions like Lipofundin MCT/LCT 20% should be preferred over lower concentrated lipid emulsions. Elderly patients Caution should be exercised in patients suffering from further diseases like cardiac insufficiency or renal insufficiency that may frequently be associated with advanced age.
1. g. 4) ● Decompensated cardiac insufficiency ● Acute pulmonary oedema
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Medium Chain Triglycerides in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Fat overload syndrome Overdose of lipid emulsion or impaired capacity to eliminate triglycerides can lead to “fat overload syn-drome”. Possible signs of metabolic overload must be observed. The cause may be genetic (individually different metabolism) or the fat metabolism may be affected by ongoing or previous diseases.
This syndrome may also appear during severe hypertriglyceridaemia, even at the recommended infusion rate, and in association with a sudden change in the patient’s clinical condition, such as renal function impairment or infection. The fat overload syndrome is characterised by hyperlipidaemia, fever, fat infiltration, hepatomegaly with or without icterus, splenomegaly, anaemia, leukopenia, thrombocytopenia, coagulation disorder, haemolysis and reticulocytosis, abnormal liver function tests and coma.
The symptoms are usually reversible if the infusion of the fat emulsion is discontinued. Should signs of a fat overload syndrome occur, the infusion of Lipofundin MCT/LCT 20% must be discon-tinued immediately. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
g. renal insufficiency, diabetes mellitus, pancreatitis, impaired hepatic function, hypothyroidism (with hypertriglyceridaemia), and sepsis. If Lipofundin MCT/LCT 20% is administered to patients with these conditions, close monitoring of serum triglycerides is necessary.
The dose should be adjusted to the metabolic tolerance. The presence of hypertriglyceridaemia 12 hours after lipid administration also indicates a disturbance of lipid metabolism. Paediatric population Free fatty acids (FFA) compete with bilirubin for albumin binding sites.
Especially very premature infants may be at increased risk of hyperbilirubinaemia due to high levels of FFA released from triglycerides resulting in a high FFA/albumin ratio. In parenterally fed infants at risk of hyperbilirubinaemia, serum triglyceride and bilirubin levels should be monitored and lipid infusion rate be adjusted if deemed necessary.
During infusion Lipofundin MCT/LCT 20% should be protected from phototherapy light to decrease the formation of potentially harmful triglyceride hydroperoxides. The serum triglyceride concentration should be regularly monitored during the infusion of Lipofundin MCT/LCT 20%, especially if there is an increased risk of hyperlipidaemia.
A stepwise increase of the daily dose may be advisable. Depending on the patient’s metabolic condition, occasional hypertriglyceridaemia may occur. 8 mmol/l. 5 mmol/l. Light exposure of mixtures for intravenous parenteral nutrition, especially after admixture with trace elements and/or vitamins, may have adverse effects on clinical outcome in neonates, due to generation of peroxides and other degradation products.
6). Interference with laboratory tests Lipids may interfere with certain laboratory tests (such as bilirubin, lactate dehydrogenase, oxygen saturation) when the blood sample is taken before the lipids have been eliminated from the bloodstream; this may take 4 to 6 hours.